Enliven Therapeutics, Inc. Stock Price

NasdaqGS:ELVN Community·US$1.2b Market Cap

0 Narratives written by author
0 Comments on narratives written by author
0 Fair Values set on narratives written by author

Create a narrative

ELVN Share Price Performance

US$20.61

-8.05 (-28.09%)

US$20.61

-8.05 (-28.09%)

US$20.61

Sun, 26 Oct 25

Share PriceUS$20.61

ELVN Community Narratives

There are no narratives available yet.

Create a narrative

There are no community narratives available.

Snowflake Analysis

Flawless balance sheet with slight risk.

4 Risks

2 Rewards

View Full Analysis

Enliven Therapeutics, Inc. Key Details

Last Reported Earnings

Jun 30, 2025

Next Reporting Earnings

n/a

: -1.69
: 0%
: 0%
: 0%

View Full Analysis

About ELVN

Founded: n/a
Employees: 63
CEO: Samuel Kintz
WebsiteView website: www.enliventherapeutics.com

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a CNS penetrant and irreversible HER2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 driven cancers and solid tumors. The company is headquartered in Boulder, Colorado.